Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 26, 2023 07:30 ET | Source: Incannex Healthcare

Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis

MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
July 21, 2023 09:09 ET | Source: Incannex Healthcare

Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea

MELBOURNE, Australia, July 21, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
July 18, 2023 07:40 ET | Source: Incannex Healthcare

Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea

Highlights: Incannex has engaged Fortrea as the contract research organisation (‘CRO’) to manage the IND opening Phase 2/3 clinical trial investigating IHL-42X for treatment of OSA.The Phase 2/3...
July 13, 2023 08:00 ET | Source: Incannex Healthcare

Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis

Highlights: Incannex has received approval from HREC for the lead site, Emeritus Research, Camberwell, VIC for the Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Effect on Pain...
July 10, 2023 07:30 ET | Source: Incannex Healthcare

Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq

Highlights: Incannex to redomicile to the United States via a Scheme of Arrangement pursuant to Australian lawA newly formed Delaware corporation (Incannex Healthcare Inc.) will become the ultimate...
July 06, 2023 08:42 ET | Source: Incannex Healthcare

Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’s Proprietary Drug for Treatment of Obstructive Sleep Apnoea (‘OSA’)

Highlights: Incannex has received approval from Bellberry Human Research Ethics Committee (‘HREC’) to commence the bioavailability/bioequivalence (‘BA/BE’) clinical trial to assess the...
June 23, 2023 08:00 ET | Source: Incannex Healthcare

Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023

MELBOURNE, Australia, June 23, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing medicinal cannabinoid...
June 16, 2023 08:00 ET | Source: Incannex Healthcare

Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial

MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
May 30, 2023 08:00 ET | Source: Incannex Healthcare

World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board

Highlights: Three world-leading clinical psychedelics experts join Clarion Clinics Advisory Board.Dr. Bill Richards is among the world’s best known psychedelic researchers and practitioners. He has...
May 16, 2023 07:50 ET | Source: Incannex Healthcare

Incannex Company Presentation – Presentation of Psychennex, Psychedelic Therapies Subsidiary Company

MELBOURNE, Australia, May 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation which details...